Laparoscopic Radical Hysterectomy Results in Higher Recurrence Rate Versus Open Abdominal Surgery for Stage IB1 Cervical Cancer Patients With Tumor Size Less Than 2 Centimeter: A Retrospective Propensity Score-Matched Study

Xiaoyue Chen1, Jiangtao Yu2, Hongqin Zhao2, Yan Hu2† and Haiyan Zhu1†

1 Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China, 2 Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Objectives: To compare the oncologic outcomes between laparoscopic and open radical hysterectomy in patients with stage IB1 cervical cancer lesion less than 2 cm.

Methods: Patients diagnosed FIGO (2009) stage IB1 (tumor diameter <2 cm) and underwent radical hysterectomy in our hospital between March 2008 and November 2018 were studied. A propensity-matched comparison (1:2) was conducted to minimize selection biases. Demographic and baseline oncologic characteristics were balanced between groups. Overall survival (OS) and disease-free survival (DFS) were assessed using the Kaplan–Meier model, along with univariable and multivariable regression analysis.

Results: A total of 261 patients were enrolled in this study after propensity-matching, with 174 in the open group and 87 in the laparoscopic group. Disease relapsed in seven patients in the laparoscopy group, and the recurrence rate was 8.0% (7/87). There were eight patients underwent abdominal radical hysterectomy experienced recurrence, and the recurrence rate was 4.6% (8/174). The multivariate analysis model revealed that laparoscopic operation was associated with higher risk of recurrence than abdominal radical hysterectomy (HR, 3.789; 95% CI, 1.143–12.559; p = 0.029). There were five patients or 2.9% (5/174) died in open surgery group and the corresponding percentage in laparoscopy group was 2.3% (2/87). No difference was found in OS between the two groups (HR, 1.823; 95% CI, 0.2673–12.44; log-rank p = 0.5398). All the recurrence occurred within two years after operation in the laparoscopy group, among which pelvic recurrence (85.7%) was dominant.
INTRODUCTION

Cervical cancer is a disease that is curable with early diagnosis and intervention, yet it remains the fourth leading cause of cancer-related death worldwide (1). Radical hysterectomy (RH) with bilateral pelvic lymph node dissection represents the first-line treatment for early-stage cervical cancer (2). The advantages and disadvantages of laparoscopic RH are controversial since the first case of a laparoscopic RH and paraaortic and pelvic lymphadenectomy was performed to treat a stage IA2 carcinoma of the cervix (3). Laparoscopic RH has gradually emerged as an alternative procedure for cervical cancer treatment in the last decade in China due to the improved laparoscopic equipment and accumulated experience and expertise of oncologists. More importantly, previous studies showed that patients could benefit from laparoscopic surgery with similar survival outcomes (4–8) as those who underwent laparotomy, but had better life quality after the operation (9, 10).

The published result of Laparoscopic Approach to Carcinoma of Cervix (LACC) trial challenged the oncologic safety of minimally invasive radical hysterectomy and endorsed open surgery. The phase 3 trial indicated that minimally invasive radical hysterectomy had lower disease-free survival as well as higher local recurrence rate than open surgery (11). Meanwhile, the postoperative life quality was similar between the two groups (12). The NCCN Clinical Practice Guidelines thus regarded open surgery as the standard approach for radical hysterectomy since 2019 (13).

However, LACC trial has its limitations. It cannot be generalized to patients with tumor size <2 cm, as it was not powered to evaluate the oncologic outcomes of the two surgical approaches in this context (11). So far, few articles directly explored the benefits of laparoscopic RH in cervical cancer with a foci diameter less than 2 cm (14–17).

The primary purpose of this propensity-matched retrospective observational analysis is to evaluate the oncologic outcome between laparoscopic RH and open surgery in cervical cancer patients with a lesion <2 cm. The highlight of this study is that all lesions were assessed by preoperative imaging exam, which were more practical in clinical practice. The findings of this study contribute to the growing body of evidence against the use of minimally invasive surgery for cervical cancer.

MATERIALS AND METHODS

Sample Collection

This is a retrospective observational study. Cervical cancer patients, who were diagnosed and treated at the Division of Gynecology of The First Affiliated Hospital of Wenzhou Medical University between March 2008 and November 2018, were considered for our study. The criteria of choosing patients to be included in this study were as follows (1): histological diagnosis of adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma of the cervix (2), age between 18 and 70 years old (3), International Federation of Gynecology and Obstetrics (FIGO) 2009 clinical stage IB1 with tumor size <2 cm and limited to the cervix (4), normal renal, hepatic, and cardiac function, and (5) signed informed consent and compliance to follow-up. The exclusion criteria were as follows (1): patients underwent vaginal radical hysterectomy or fertility-sparing procedures, and (2) synchronous malignancies in 5 years.

The study was approved by the First Affiliated Hospital of Wenzhou Medical University Institutional Ethics Committee for Non-Interventional Research.

Surgical and Perioperative Management

Primary preoperative evaluation consisted of a complete medical history, physical examination, laboratory examinations, electrocardiogram, pelvic ultrasonography, chest X-ray, pelvic computed tomography (CT)/magnetic resonance imaging (MRI) or positron emission tomography-computed tomography (PET-CT). Preoperative imaging assessment confirmed that there were no extratereine or lymph node metastasis. Prior to surgery, all patients underwent mechanical bowel preparation and antibiotic prophylaxis. Deep venous thrombosis prophylaxis with low-molecular-weight heparin were performed according to Caprini Risk Assessment Scale for high risk of thromboembolism (12 h before surgery and postoperatively for 4 weeks). According to the NCCN guideline, all patients underwent type C radical hysterectomy with bilateral pelvic lymphadenectomy (18, 19). All procedures were performed by skilled surgeons. The uterine manipulator used in laparoscopic RH was a modified metal uterine manipulator. There were no significant differences in the facilities available for patient care. Adjuvant treatment was recommended, according to the National Comprehensive Cancer Network (NCCN) guidelines. Adjuvant radiation therapy was suggested according to Sedlis criteria, while chemo and radiation therapy was suggested in case of positive nodes, parametrial involvement, or positive surgical margins.

Data Collection

All medical records were reviewed simultaneously by three trained residents, and independently checked by two experts to ensure the accuracy.

Patients were followed up 1 month and then every 3 months during the first 2 years after surgery, and twice a year afterwards.
At each scheduled follow-up visit, pelvic examination and squamous cell carcinoma antigen (SCC) (for squamous and adenosquamous cancer) or carbohydrate antigen 125 (CA125) (for adenocarcinoma and adenosquamous cancer) were performed. Pelvic and chest CT were tested once a year. The median follow-up time was calculated from the date of surgery. A secretary made periodic phone call to patients before scheduled outpatient follow-up visit to reduce omitted follow-ups. Dates and sites of recurrence were recorded.

Staging system and architectural grade were reported according to the FIGO statements. The World Health Organization (WHO) taxonomy was used to classify histologic subtypes. Tumor size was defined as the largest diameter of the lesion in preoperative imaging evaluation according to pelvic MRI or CT. DFS was defined as the interval from the operation to the first finding of any recurrence or last follow-up visit. OS was defined as the interval from the operation to the cervical cancer related death or last follow-up visit.

**Statistical Analysis**

Patients underwent laparoscopic radical hysterectomy (LRH) were matched 1:2 to those underwent open abdominal radical hysterectomy (ARH). Six baseline characteristics (age, histology, parametrial involvement, lymphovascular space invasion, pelvic lymph nodes, surgical margin, and depth of cervical stromal invasion) were selected as covariates in propensity score match model, and the match tolerance was set to 0.01 (Supplementary Figure 1) (20). Two-independent samples t-test and the \( \chi^2 \) test were used to analyze the clinicopathologic characteristics between the LRH and ARH. DFS and OS after surgery were estimated using the Kaplan–Meier method, and a \( p \)-value < 0.05 was considered statistically significant. The log-rank test was used to compare the risk of developing recurrence and the risk of death between the two groups over the time (21). Cox proportional risk regression models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the effect of surgical approaches on the OS and DFS (22). Statistical analysis was performed using GraphPad Prism version 6.0 (GraphPad Software, San Diego, CA, USA) and IBM-Microsoft SPSS version 22.0 (IBM Corporation, Armonk, NY, USA).

**RESULTS**

**Patient Characteristics Before and After Propensity-Matching**

Over the study period, 335 patients met our inclusion and exclusion criteria. Among them, 247 patients underwent laparotomy and 88 underwent laparoscopy surgery (Figure 1). Patients in the laparoscopy group were propensity-matched 1:2 with those in the open RH group. After propensity score matching, 261 patients (87 in the laparoscopic group and 174 in the open procedure) were included in the following analysis, and no significant differences between two groups were observed in baseline characteristics. The clinicopathologic characteristics of the two groups before and after propensity-matching are presented in Table 1. Those patients who underwent ARH were more likely to have deeper depth of cervical stromal invasion \((p = 0.047)\) and poorer differentiation \((p = 0.002)\).

**Recurrence and Survival in Propensity-Matched Cohort**

The median follow-up time was 42 months (range from 12 to 138 months). In the propensity matching cohort, there were eight
patients underwent ARH experienced recurrence, which gives a recurrence rate of 4.6% (8/174). Disease relapsed in seven patients in laparoscopy group, for which the recurrence rate was 8.0% (7/87). Two-year and 5-year DFS was 97.1% versus 92.0% (p = 0.060) and 95.4% versus 92.0% (p = 0.260) for the open versus laparoscopic groups, respectively. Interestingly, Kaplan–Meier analysis indicated that patients in the LRH group showed tendency to suffer recurrence (HR, 2.838; 95% CI, 0.888–9.032; log-rank p = 0.078), even though there was no statistics difference between the two groups. Kaplan–Meier plot of DFS after PSM are presented in Figure 2.

There were five patients or 2.9% (5/174) died in open surgery group and the corresponding percentage in laparoscopy group was 2.3% (2/87). Two-year and 5-year OS was 99.4% versus 97.7% (p = 0.218) and 97.1% versus 97.7% (p = 0.787) for the open versus laparoscopic groups, respectively. Kaplan–Meier analysis showed no difference in OS between the two groups in propensity score weighting cohort (HR, 1.823; 95% CI, 0.267–12.44; log-rank p = 0.540). Kaplan–Meier plot of OS after PSM are presented in Figure 3.

### TABLE 1 | Clinicopathologic characteristics before and after propensity score matching.

| Variables                        | Before propensity score matching | After propensity score matching |
|----------------------------------|---------------------------------|---------------------------------|
|                                  | ARH 247                         | LRH 88                          | p value   | ARH 174                         | LRH 87                          | p value   |
| Age (year, Mean ± SD)            | 51.53 ± 10.31                   | 49.36 ± 8.81                    | 0.079     | 48.00 ± 14.00                   | 49.00 ± 12.00                    | 0.979     |
| Histology (%)                    | 0.153                           |                                 |           | 0.388                           |                                 |           |
| Squamous                         | 205 (82.99)                     | 66 (75.00)                      |           | 140 (80.48)                     | 66 (75.86)                      |           |
| Adenocarcinoma                   | 32 (12.96)                      | 19 (21.59)                      |           | 27 (15.52)                      | 18 (20.69)                      |           |
| Adenosquamous                    | 10 (4.05)                       | 3 (3.41)                        |           | 7 (4.02)                        | 3 (3.45)                        |           |
| Differentiation (%)              | 0.002*                          |                                 |           | 0.676                           |                                 |           |
| G1/G2                            | 92 (37.25)                      | 34 (38.64)                      |           | 58 (33.33)                      | 30 (34.48)                      |           |
| G3                               | 110 (44.53)                     | 24 (27.27)                      |           | 77 (44.25)                      | 34 (39.08)                      |           |
| Unknown/missing                  | 45 (18.20)                      | 30 (34.10)                      |           | 39 (22.40)                      | 23 (26.44)                      |           |
| Surgical margin (%)              |                                 | 1.000                           |           |                                 | 1.000                           |           |
| Negative                         | 245 (99.19)                     | 87 (98.86)                      |           | 173 (99.43)                     | 86 (98.85)                      |           |
| Positive                         | 2 (0.81)                        | 1 (1.14)                        |           | 1 (0.57)                        | 1 (1.15)                        |           |
| Pelvic lymph nodes (%)           | 0.340                           |                                 |           | 1.000                           |                                 |           |
| Negative                         | 227 (91.90)                     | 84 (95.45)                      |           | 166 (95.40)                     | 83 (95.40)                      |           |
| Positive                         | 20 (8.10)                       | 4 (4.55)                        |           | 8 (4.60)                        | 4 (4.60)                        |           |
| LVSI (%)                         | 0.638                           |                                 |           | 0.856                           |                                 |           |
| Negative                         | 199 (80.57)                     | 74 (83.15)                      |           | 148 (85.08)                     | 73 (83.91)                      |           |
| Positive                         | 48 (19.43)                      | 15 (16.86)                      |           | 26 (14.94)                      | 14 (16.09)                      |           |
| DCSI (%)                         |                                 | 0.047*                          |           | 0.974                           |                                 |           |
| Inner 1/3                        | 128 (51.82)                     | 59 (67.05)                      |           | 118 (67.82)                     | 58 (66.67)                      |           |
| Medium 1/3                       | 72 (29.15)                      | 17 (19.32)                      |           | 32 (18.39)                      | 17 (19.54)                      |           |
| Outer 1/3                        | 47 (19.03)                      | 12 (13.64)                      |           | 24 (13.79)                      | 12 (13.79)                      |           |
| Parametrial involvement (%)      | 0.570                           |                                 |           | 1.000                           |                                 |           |
| No                               | 244 (98.79)                     | 88 (100.00)                     |           | 174 (100.00)                    | 87 (100.00)                     |           |
| Yes                              | 3 (1.21)                        | 0 (0.00)                        |           |                                 |                                 |           |
| Adjuvant treatment given (%)     | 0.370                           |                                 |           | 0.605                           |                                 |           |
| No                               | 150 (60.73)                     | 55 (62.50)                      |           | 117 (67.24)                     | 54 (62.07)                      |           |
| Radiotherapy                     | 30 (12.15)                      | 5 (6.68)                        |           | 14 (8.05)                       | 5 (5.75)                        |           |
| Chemotherapy                     | 35 (14.17)                      | 15 (17.05)                      |           | 23 (13.22)                      | 15 (17.24)                      |           |
| Concomitant chemoradiotherapy     | 32 (12.96)                      | 13 (14.77)                      |           | 20 (11.49)                      | 13 (14.94)                      |           |
| SCC before surgery (Mean ± SD)   | 1.00 ± 0.70                     | 0.90 ± 1.00                     |           | 1.00 ± 0.50                     | 0.90 ± 1.00                     |           |

ARH, abdominal radical hysterectomy; LRH, laparoscopic radical hysterectomy; LVSI, lymphovascular space invasion, DCSI, depth of cervical stromal invasion; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; LVSI, lymph vascular space invasion. Values are presented as mean ± standard deviation or number (%). *p < 0.05, statistically significant.

### Univariable and Multivariable Regression Analysis for Prognostic Factors

We performed univariable and multivariate Cox analysis to investigate the comprehensive prognostic factors for RFS (Table 2) and OS (Table 3). In univariable regression analysis of the matched cohort histology subtype adenosquamous (HR, 9.619; 95% CI, 2.545–36.353; p = 0.001) and positive pelvic lymph node (HR, 5.593; 95% CI, 1.577–19.835; p = 0.008) were potentially predictive factors of prognosis for RFS. The multivariate analysis model revealed histology subtype adenosquamous (HR, 8.919; 95% CI, 1.978–40.227; p = 0.004), positive pelvic lymph node (HR, 5.593; 95% CI, 1.577–19.835; p = .008) as well as laparoscopic operation procedure (HR, 3.789; 95% CI, 1.143–12.559; p = 0.029) were potentially predictive factors of DFS. Univariate Cox proportional hazard regression analysis revealed that positive pelvic lymph node (HR, 8.439; 95% CI, 1.637–43.504; p = 0.011), histology subtype adenosquamous (HR, 13.132; 95% CI, 1.187–145.267; p = 0.036) and adenocarcinoma (HR, 11.074; 95% CI, 2.019–60.733; p = 0.006) were predictors of OS. Furthermore, the multivariate survival analysis model revealed that the adenosquamous (HR, 17.662; 95% CI,
1.837–169.853; \( p = 0.013 \), adenocarcinoma (HR, 20.647; 95% CI, 1.234–345.376; \( p = 0.035 \)) and positive pelvic lymph node (HR, 11.372; 95% CI, 1.890–68.440; \( p = 0.008 \)) were potentially predictive factors of OS.

The Pattern of Recurrence

All the recurrence occurred within two years after operation in the laparoscopy group, while in the open surgery group, five cases relapsed within 2 years and the other three cases recurred within 5 years. When it comes to the recurrence type, most of the cases in the laparoscopic group suffered pelvic recurrence (6/7, 85.7%), and one case suffered vaginal stump recurrence. In the laparotomy group, two cases experienced vaginal stump recurrence, four cases experienced hematogenous recurrences (one case liver and lung recurrences, one case liver and two cases lung), and two cases suffered pelvic recurrence.

DISCUSSION

Although the safety of minimal invasive surgery in cervical cancer was questioned since the published result of LACC trial
in 2018 (23), its advantages are undeniable. These advantages include less intraoperative blood loss, a shorter length of hospital stay, faster bowel and bladder function recovery, and a lower risk of postoperative complications (24, 25). Gynecological oncologists are trying to select patients with specific characteristics, who might benefit from minimal invasive surgery (26). Tumor dimension is one of the most studied specific characteristics. A consensus has been reached that there was no distinct advantage of LRH over ARH in tumors diameter > 2 cm (11). However, the exact effect of surgical approach on oncological outcomes in patients with tumor diameter < 2 cm is still controversial, and the related studies are limited.

Some studies found similar hazards of recurrence and death in both subgroups. Kim et al. reported that minimal invasive surgery did not influence PFS of stage IB1 patients with cervical mass ≤ 2 cm on pre-operative MRI (14). No difference in DFS was noted between robotic and open RH in cervical cancer tumor size ≤ 2 cm in a Sweden cohort (17). These results were supported by a multicenter retrospective study published by Chinese researchers (15). Recently, several studies reached the conclusion that minimally invasive RH had inferior DFS even for tumors that have size less than 2 cm. A multi-institutional retrospective study performed in the United States found that patients with tumor size ≤ 2 cm on final pathology had a higher recurrence rate in the minimally invasive approach (27). A Korean Gynecologic Oncology Group Study reached conclusion that LRH was associated with inferior DFS among patients with IB – IIA and tumor size < 2 cm (16). There has been no widely accepted conclusion on the exact effect of surgical approach on oncological outcomes in tumor diameter < 2 cm so far. On the other hand, there is a lack of uniformity in definition between different studies (i.e., tumor size based on MRI, clinical examination, or pathology; lesion diameter < 2 cm or ≤ 2 cm; Da Vinci Robotic Surgery included or excluded; 3D laparoscopy or not; FIGO 2009 or 2018). In this study, we analyzed the clinical data from our center to explore the safety of LRH in FIGO 2009 stage IB1 cervical cancer patients with tumor diameter < 2 cm in preoperative imaging exam. We concluded that LRH was associated with higher risk of recurrence than ARH and there is no difference between two groups in OS.

The multivariate analysis revealed that histology subtype adenosquamous, positive pelvic lymph node as well as laparoscopic operation procedure were potentially predictive factors of DFS. Adenosquamous, adenocarcinoma, and positive pelvic lymph node were potentially predictive factors for OS. We included those variables that were reported as risk factors for

| Characteristics                      | Univariate HR (95% CI) | P     | Multivariate HR (95% CI) | P     |
|--------------------------------------|------------------------|-------|--------------------------|-------|
| Histology                            |                        |       |                          |       |
| Squamous                             | Reference              |       | Reference                |       |
| Adenocarcinoma                       | 2.457 (0.739–8.171)    | 0.143 | 2.536 (6.818–10.404)     | 0.196 |
| Adenosquamous                        | 9.619 (2.545–36.553)   | 0.001*| 8.919 (1.978–40.227)     | 0.004*|
| Surgery Approach                     |                        |       |                          |       |
| Open                                 | Reference              |       | Reference                |       |
| Laparoscope                          | 1.405 (0.143–3.145)    | 0.088 |                         |       |
| Parametrial Involvement              |                        |       |                          |       |
| No                                   | Reference              |       | Reference                |       |
| Yes                                  | 5.169 (0.699–38.231)   | 0.108 |                         |       |
| Pelvic lymph node                    |                        |       |                          |       |
| Negative                             | Reference              |       | Reference                |       |
| Positive                             | 5.939 (1.577–19.835)   | 0.008*|                         |       |
| Surgical Margin                      |                        |       |                          |       |
| Negative                             | Reference              |       | Reference                |       |
| Positive                             | 0.049 (0.000–400413)   | 0.814 |                         |       |
| LVSI                                 |                        |       |                          |       |
| Negative                             | Reference              |       | Reference                |       |
| Positive                             | 0.739 (0.208–2.619)    | 0.639 |                         |       |
| DCSI                                 |                        |       |                          |       |
| Inner 1/3                            | Reference              |       | Reference                |       |
| Medium 1/3                           | 0.568 (0.151–2.147)    | 0.406 |                         |       |
| Outer 1/3                            | 1.056 (2.386–4.718)    | 0.944 |                         |       |
| Differentiation                      |                        |       |                          |       |
| G1/G2                                | Reference              |       | Reference                |       |
| G3                                   | 1.168 (0.515–2.649)    | 0.709 |                         |       |
| Unknown/missing                      | 0.525 (0.146–1.881)    | 0.322 |                         |       |
| Adjuvant Therapy                     |                        |       |                          |       |
| No                                   | Reference              |       | Reference                |       |
| Radiotherapy                         | 0.819 (0.177–3.793)    | 0.799 |                         |       |
| Chemotherapy                         | 2.795 (0.985–7.857)    | 0.984 |                         |       |
| Chemoradiotherapy                    | 1.612 (0.295–8.806)    | 0.581 |                         |       |

LVSI, lymphovascular space invasion. DCSI, depth of cervical stromal invasion; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated.

*P < 0.05.
recurrence in the multivariate analyses (28, 29). Several variables showed no association with survival in univariate analysis in our study, including LVSI, depth of invasion, tumor grade, surgical margins, etc., which are typically associated worse outcomes. This situation might be explained by the small sample size and/or the uneven distribution between subgroups. Meanwhile, it is undeniable that these factors might, to a certain extent, influence the route of surgery. Doctors are more likely to perform open surgery on those patients with poor differentiation, deeper invasion and LVSI. There might be inter-operator variation in surgical treatment of cervical cancer between different surgeons.

The diameter of the tumor was measured via preoperative pelvic imaging evaluation according to MRI or CT in our study. Preoperative imaging assessment was more valuable and practical in clinical practice, and it is an important factor for surgeons to decide the route of surgery. There are still some differences between the preoperative imaging (CT or MRI) and the pathologic report. Although postoperative pathology could be interfered by preoperative conization and specimen treatment, it is still the gold standard of final diagnosis and stage. We had encountered the patients who had been underestimated by preoperative imaging assessment. How to accurately predict the tumor size and stage before surgery is a valuable research field.

Our results indicated that cervical cancer patients with a lesion less than 2 cm, who underwent LRH, were more likely to experience recurrence than those underwent ARH. In our study, all the recurrence in the laparoscopic group occurred within 2 years after surgery, and most of the recurrence occurred in pelvic. Our result was similar with the results from a study in South Korea (14). There are several potential reasons contributing to the higher recurrence for LRH. The uterine manipulator and the exposure of cervical cancer to circulating CO2 might increase tumor spillage (23). Besides, the prolonged Trendelenburg position (30) might also influence the relapse of cancer. A constructive manner to limit the use of invasive uterine manipulator and the time interval of opening the vagina should be taken into consideration. Intraperitoneal tumor exposure was an independent prognostic factor for worse survival (31). A novel fluorescence imaging-based tool for feasible and direct visualization of peritoneal contamination

### Table 3 | Factors Associated with Overall Survival

| Characteristics       | Univariate HR (95% CI) | P       | Multivariate HR (95% CI) | P       |
|-----------------------|------------------------|---------|--------------------------|---------|
|                       |                        |         |                          |         |
| Histology             |                        |         |                          |         |
| Squamous Reference    |                        |         |                          |         |
| Adenocarcinoma        | 11.074 (2.019–60.733)  | 0.006*  | 20.647 (1.234–345.376)   | 0.013*  |
| Adenosquamous         | 13.132 (1.187–145.267) | 0.036*  | 17.662 (1.837–169.853)   | 0.035*  |
| Surgery Approach      |                        |         |                          |         |
| Open Reference        |                        |         |                          |         |
| Laparoscope           | 1.694 (0.309–9.296)    | 0.544   |                          |         |
| Parametrial Involvement |                     |         |                          |         |
| No Reference          |                        |         |                          |         |
| Yes                   | 0.848 (0.000–43)       | 0.767   |                          |         |
| Pelvic lymph node     |                        |         |                          |         |
| Negative Reference    |                        |         |                          |         |
| Positive              | 8.439 (1.637–43.504)   | 0.011*  | 11.372 (1.890–68.440)    | 0.008*  |
| Surgical Margin       |                        |         |                          |         |
| Negative Reference    |                        |         |                          |         |
| Positive              | .049 (0.000–5.48E15)   | 0.880   |                          |         |
| LVSI                  |                        |         |                          |         |
| Negative Reference    |                        |         |                          |         |
| Positive              | 1.083 (0.130–9.001)    | 0.941   |                          |         |
| DCSI                  |                        |         |                          |         |
| Inner 1/3 Reference   |                        |         |                          |         |
| Medium 1/3            | 2.325 (0.388–13.918)   | 0.355   |                          |         |
| Outer 1/3             | 2.979 (0.497–17.838)   | 0.232   |                          |         |
| Differentiation       |                        |         |                          |         |
| G1/G2 Reference       |                        |         |                          |         |
| G3                    | 0.932 (0.178–2.247)    | 0.478   |                          |         |
| Unknown/missing       | 0.343 (0.041–2.850)    | 0.322   |                          |         |
| Adjuvant Therapy      |                        |         |                          |         |
| No Reference          |                        |         |                          |         |
| Radiotherapy          | 0.529 (0.055–5.089)    | 0.582   |                          |         |
| Chemotherapy          | 0.000 (.000)           | 0.986   |                          |         |
| Chemoradiotherapy     | 2.471 (.257–23.772)    | 0.433   |                          |         |
| Relapse               |                        |         |                          |         |
| No Reference          |                        |         |                          |         |
| Yes                   | 1.000 (.024–42.036)    | 1.000   |                          |         |

LVSI, lymphovascular space invasion; DCSI, depth of cervical stromal invasion; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated. *P < 0.05.
during colpotomy might serve as a quality assessment tool for surgeons and surgical techniques (32). Specific measures were adopted by some surgeons to prevent tumor spillage during LRH, such as creation of a vaginal cuff, minimized handling of the uterine cervix, and bagging the specimen (33). Recently, a multicenter retrospective observational cohort study concluded that conization before radical hysterectomy was associated with improved DFS in FIGO 2009 stage IB1 cervical cancer, and no conization before radical hysterectomy was an independent factor for higher risk of recurrence (34). However, whether conization before surgery would influence the oncologic outcomes between laparoscopic and open radical hysterectomy is still unknown and is an interesting direction for further study.

The current study had several limitations. First, this is a retrospective study. The heterogeneity differences between treatment groups still existed, even though propensity score matching was performed. Second, there might be inter-operator variation in surgical treatment of cervical cancer between different surgeons. Third, the sample size is small and the distribution of subgroup is uneven. Prospective multicenter studies are still needed to confirm our findings. Fourth, there might be some difference between the preoperative imaging modality (CT or MRI) and the actual pathologic tumor size. Pathological tumor size should be taken into consideration in future study.

In conclusion, we observed that cervical cancer patients with a lesion less than 2 cm might be more likely to have recurrence in LRH group than those taken ARH. Further randomized controlled perspective trials are needed to explore the advantages and disadvantages of the adoption of minimally invasive techniques in the treatment of cervical cancer patients with a lesion less than 2 cm.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

AUTHOR CONTRIBUTIONS

XC performed data analysis, reviewed the literature and drafted the article. JY collected clinical data. HYZ and YH designed the study and finalized the paper. HQZ and YH provided suggestions to improve it. All authors contributed to the article and approved the submitted version.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.683231/full#supplementary-material

Supplementary Figure 1 | Diagram of propensity score matching.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 68 (6):394–424. doi: 10.3322/caac.21492
2. Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, et al. Nccn Guidelines Insights: Cervical Cancer, Version 1.2020. J Natl Compr Canc Netw (2020) 18(6):660–8. doi: 10.6004/jnccn.2020.0027
3. Nezhat CR, Burrell MO, Nezhat FR, Benigno BB, Welander CE. Laparoscopic Radical Hysterectomy With Paraaortic and Pelvic Node Dissection. Am J Obstet Gynecol (1992) 166(3):864–5. doi: 10.1016/0002-9378(92)91351-a
4. Malzoni M, Tinelli R, Cosentino F, Fusco A, Malzoni C. Total Laparoscopic Radical Hysterectomy Versus Abdominal Radical Hysterectomy With Lymphadenectomy in Patients With Early Cervical Cancer: Our Experience. Ann Surg Oncol (2009) 16(5):1516–23. doi: 10.1245/s10434-009-0342-7
5. Ditto A, Martinelli F, Bogani G, Gasparri ML, Di Donato V, Zanaboni F, et al. Implementation of Laparoscopic Approach for Type B Radical Hysterectomy: A Comparison With Open Surgical Operations. Eur J Surg Oncol (2015) 41 (1):34–9. doi: 10.1016/j.ejso.2014.10.058
6. Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV3rd, Micha JP, Lopez KL, et al. Survival Rate Comparisons Amongst Cervical Cancer Patients Treated With an Open, Robotic-Assisted or Laparoscopic Radical Hysterectomy: A Five Year Experience. Surg Oncol (2016) 25(1):66–71. doi: 10.1016/j.suronc.2015.09.004
7. Diver E, Hinchcliff E, Gockley A, Melamed A, Contrino L, Feldman S, et al. Minimally Invasive Radical Hysterectomy for Cervical Cancer Is Associated With Reduced Morbidity and Similar Survival Outcomes Compared With Laparotomy. J Minim Invasive Gynecol (2017) 24(3):402–6. doi: 10.1016/j.jmig.2016.12.005
8. Li G, Yan X, Shang H, Wang G, Chen L, Han Y. A Comparison of Laparoscopic Radical Hysterectomy and Pelvic Lymphadenectomy and Laparotomy in the Treatment of Ib-IaA Cervical Cancer. Gynecol Oncol (2007) 105(1):176–80. doi: 10.1016/j.ygyno.2006.11.011
9. Xiao M, Gao H, Bai H, Zhang Z. Quality of Life and Sexuality in Disease-Free Survivors of Cervical Cancer After Radical Hysterectomy Alone: A Comparison Between Total Laparoscopy and Laparotomy. Med (Baltimore) (2016) 95(6):e4787. doi: 10.1097/MD.0000000000004787
10. Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhungar A, Wharton JT, et al. Quality of Life and Sexual Functioning in Cervical Cancer Survivors. J Clin Oncol (2005) 23(30):7428–36. doi: 10.1200/JCO.2004.00.3996
11. Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, et al. Minimally Invasive Versus Abdominal Radical Hysterectomy for Cervical Cancer. N Engl J Med (2018) 379(20):1895–904. doi: 10.1056/NEJMoa1806395
12. Frumovitz M, Obermair A, Coleman RL, Pareja R, Lopez A, Riberio R, et al. Quality of Life in Patients With Cervical Cancer After Open Versus Minimally Invasive Radical Hysterectomy (LACC): A Secondary Outcome of a Multicentre, Randomised, Open-Label, Phase 3, non-Inferiority Trial. Lancet Oncol (2020) 21(6):851–60. doi: 10.1016/S1470-2045(20)30081-4
13. Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, et al. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw (2019) 17(1):64–84. doi: 10.6004/jnccn.2019.0001
14. Kim SL, Cho JH, Seol A, Kim YI, Lee M, Kim HS, et al. Comparison of Survival Outcomes Between Minimally Invasive Surgery and Conventional Open Surgery for Radical Hysterectomy as Primary Treatment in Patients With Stage Ib1-IaA2 Cervical Cancer. Gynecol Oncol (2019) 153(1):3–12. doi: 10.1016/j.ygyno.2019.01.008
15. Li P, Chen L, Ni Y, Liu J, Li D, Guo J, et al. Comparison Between Laparoscopic and Abdominal Radical Hysterectomy for Stage IB1 and Tumor Size <2 Cm Cervical Cancer With Visible or Invisible Tumors: A Multicentre Retrospective Study. J Gynecol Oncol (2020) 32(2):e17. doi: 10.3802/jgo.2021.32.e17
16. Paik ES, Lim MC, Kim MH, Kim YH, Song ES, Seong SJ, et al. Comparison of Laparoscopic and Abdominal Radical Hysterectomy in Early Stage Cervical...
Cancer Patients Without Adjuvant Treatment: Ancillary Analysis of a Korean Gynecologic Oncology Group Study (Kgog 1028). Gynecol Oncol (2019) 154 (3):547–53. doi: 10.1016/j.ygyno.2019.06.023
17. Alfonzo E, Wallin E, Ekdahl L, Staf C, Radestad AF, Reynisson P, et al. No Survival Difference Between Robotic and Open Radical Hysterectomy for Women With Early-Stage Cervical Cancer: Results From a Nationwide Population-Based Cohort Study. Eur J Cancer (2019) 116:19–77. doi: 10.1016/j.ejca.2019.05.016
18. Querleu D, Morrow CP. Classification of Radical Hysterectomy. Lancet Oncol (2008) 9(3):297–303. doi: 10.1016/S1470-2245(08)70074-3
19. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, et al. Survival After Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. N Engl J Med (2018) 379(20):1905–14. doi: 10.1056/NEJMoai1804923
20. Kaplan EL MP. Nonparametric Estimation From Incomplete Observations. J Am Stat Assoc (1958) 53(282):457–81. doi: 10.1080/01621459.1958.10501452
21. Mantel N. Evaluation of Survival Data and Two New Rank Order Statistics Arising in its Consideration. Cancer Chemother Rep (1966) 50(3):163–70.
22. Cox DR. Models and Life-Tables Regression. J R Stat Soc Ser B (Methodological) (1972) 34(2):187–220. doi: 10.1111/j.2517-6161.1972.tb00899.x
23. Melamed A, Margul DJ, Chen L, Keating NL, Del Carmen MG, Yang J, et al. Survival After Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. N Engl J Med (2018) 379(20):1905–14. doi: 10.1056/NEJMoai1804923
24. Querleu D, Leblanc E, Ferron G, Narducci F. Laparoscopic Surgery in Gynaecological Oncology. Eur J Surg Oncol (2006) 32(8):853–8. doi: 10.1016/j.ejso.2006.03.043
25. Zeng YC, Ching SS, Loke AY. Quality of Life Measurement in Women With Early-Stage Cervical Cancer: Implications for Chinese Cervical Cancer Survivors. Health Qual Life Outcomes (2010) 8:30. doi: 10.1186/1477-7525-8-30
26. Pedone Anchora L, Turco LC, Bizzarri N, Capozzi VA, Lombisani A, Chiantera V, et al. How to Select Early-Stage Cervical Cancer Patients Still Suitable for Laparoscopic Radical Hysterectomy: A Propensity-Matched Study. Ann Surg Oncol (2020) 27(6):1947–55. doi: 10.1245/s10434-019-08162-5
27. Uppal S, Gehrig PA, Peng K, Bixel KL, Matsuo K, Vetter MH, et al. Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study. J Clin Oncol (2020) 38(10):1030–40. doi: 10.1200/JCO.19.03012
28. Liontos M, Kyriazoglou A, Dimitriadis I, Dimopoulos MA, Bamias A. Systemic Therapy in Cervical Cancer: 30 Years in Review. Crit Rev Oncol Hematol (2019) 137(3):17–57. doi: 10.1016/j.critrevonc.2019.02.009
29. Leath CA3rd, Monk BJ. Twenty-First Century Cervical Cancer Management: A Historical Perspective of the Gynecologic Oncology Group/NRG Oncology Over the Past Twenty Years. Gynecol Oncol (2018) 150(3):391–7. doi: 10.1016/j.ygyno.2018.06.023
30. Tewari KS. Minimally Invasive Surgery for Early-Stage Cervical Carcinoma: Interpreting the Laparoscopic Approach to Cervical Cancer Trial Results. J Clin Oncol (2019) 37(33):3075–80. doi: 10.1200/JCO.19.02024
31. Pedone Anchora L, Bizzarri N, Kucukmetin A, Turco LC, Gallotta V, Carbone V, et al. Investigating the Possible Impact of Peritoneal Tumor Exposure Amongst Women With Early Stage Cervical Cancer Treated With Minimally Invasive Approach. Eur J Surg Oncol (2020) 47(5):1090–7. doi: 10.1016/j.ejso.2020.09.038
32. Klappod R, Hertel H, Hillemanns P, Rottger M, Soergel P, Kuehnle E, et al. Peritoneal Contamination With ICG-stained Cervical Secretion as Surrogate for Potential Cervical Cancer Tumor Cell Dissemination: A Proof-of-Principle Study for Laparoscopic Hysterectomy. Acta Obstet Gynecol Scand (2019) 98 (11):1398–403. doi: 10.1111/aogs.13681
33. Kanao H, Matsu K, Aoki Y, Tanigawa T, Nomura H, Okamoto S, et al. Feasibility and Outcome of Total Laparoscopic Radical Hysterectomy With No-Look No-Touch Technique for FIGO IB1 Cervical Cancer. J Gynecol Oncol (2019) 30(3):e71. doi: 10.3802/jgo.2019.30.e71
34. Bizzarri N, Pedone Anchora L, Kucukmetin A, Ratnavelu N, Korompelis P, Carbone V, et al. Protective Role of Conization Before Radical Hysterectomy in Early-Stage Cervical Cancer: A Propensity-Score Matching Study. Ann Surg Oncol (2021). doi: 10.1245/s10434-021-09695-4

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Chen, Yu, Zhao, Hu and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.